戒菸及尼古丁戒菸市場機會、成長動力、產業趨勢分析及預測（2025-2034）

2024 年全球戒菸和尼古丁脫癮市場規模達到 255 億美元，預計 2025 年至 2034 年期間的複合年成長率為 12%。人們越來越意識到吸菸帶來的嚴重健康風險，包括肺癌、心血管疾病和呼吸道疾病，這推動了尼古丁脫癮產品的需求。政府推動的反吸煙運動、對菸草產品的更嚴格監管以及消費者對更健康替代品的偏好不斷上升，進一步加速了市場擴張。

隨著人們對戒菸計畫、尼古丁替代療法 (NRT) 和先進藥物配方的日益重視，市場將在未來十年實現大幅成長。此外，藥物的進步和下一代尼古丁替代解決方案（如處方藥和行為支持療法）的引入使人們更容易成功戒菸。提供戒菸支援的數位健康平台和行動應用程式的日益普及，進一步促進了人們對這些解決方案的認知和可及性的提高。

市場按產品類型分類，包括尼古丁替代療法 (NRT)、藥物療法以及電子煙和蒸氣煙。 2024 年，電子煙和蒸氣煙領域將佔據市場主導地位，佔總佔有率的 50%。人們越來越喜歡這些替代品，因為人們認為它們與傳統香菸相比危害較小。年輕人，尤其是北美和歐洲的年輕人，正引領著電子煙設備的潮流，他們被電子煙的便利性、口味多樣性和技術進步所吸引。越來越多的監管機構批准透過電子煙產品來控制尼古丁輸送，以及主要參與者對創新減害技術的投​​資不斷增加，進一步推動了該領域的成長。

依給藥途徑考察市場時，可分為口服、經皮、鼻腔、吸入及舌下給藥方式。 2024年，吸入劑領域將佔據市場主導地位，佔有50%的佔有率。該領域的主導地位很大程度上歸因於尼古丁吸入器、蒸氣煙和電子香菸的日益普及。隨著吸入療法的不斷進步，製造商推出了新型尼古丁吸入器，旨在提供可控劑量的尼古丁，增強其作為戒菸輔助的有效性。消費者偏好吸入式吸煙方式，是因為它們能夠複製傳統吸煙的體驗，同時最大限度地減少接觸有害化學物質。

2024 年美國戒菸和尼古丁戒菸市場價值為 89 億美元，預計到 2034 年將達到 267 億美元。美國肺癌和其他吸菸相關疾病的盛行率不斷上升，推動了對戒菸產品的需求。越來越多的吸菸者，特別是年輕人，正在積極尋求傳統香菸的替代品，導致對 NRT、處方藥和行為療法的需求激增。電子煙和蒸氣煙作為戒菸過渡輔助工具的廣泛採用進一步支持了市場的成長。預計不斷擴大的研發力度以及政府支持的反吸煙措施將在未來幾年為市場參與者創造重大機會。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 人們對吸煙相關健康風險的認知不斷提高
    • 政府法規和反吸煙運動
    • 戒菸產品的進步
    • 吸煙相關疾病和醫療成本上升
  • 產業陷阱與挑戰
    • 戒菸產品成本高
    • 心理和生理成癮挑戰
• 成長潛力分析
• 技術格局
• 監管格局
• 差距分析
• 專利分析
• 波特的分析
• PESTEL 分析

第4章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：依產品類型，2021 年至 2034 年

• 主要趨勢
• 尼古丁替代療法
  • 尼古丁口香糖
  • 尼古丁貼片
  • 尼古丁含片
  • 尼古丁鼻噴劑
  • 尼古丁吸入器
• 藥物治療
  • 伐尼克蘭（Chantix）
  • 安非他酮（Zyban）
• 電子煙和蒸氣煙

第6章：市場估計與預測：依管理路線，2021 年至 2034 年

• 主要趨勢
• 口服
• 經皮
• 鼻腔
• 吸入
• 舌下

第7章：市場估計與預測：按配銷通路，2021 年至 2034 年

• 主要趨勢
• 醫院藥房
• 零售藥局
• 電子商務

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Alkalon
• British American Tobacco
• Cipla
• Dr. Reddy's Laboratories
• GlaxoSmithKline
• Imperial Brands
• Johnson & Johnson
• Lupin
• NJOY
• Novartis
• Perrigo Company
• Pfizer
• Philip Morris International
• Rusan Pharma
• Zydus Group

The Global Smoking Cessation And Nicotine De-Addiction Market reached USD 25.5 billion in 2024 and is projected to grow at a CAGR of 12% between 2025 and 2034. The increasing awareness of the severe health risks associated with smoking, including lung cancer, cardiovascular diseases, and respiratory disorders, is fueling the demand for nicotine de-addiction products. Government initiatives promoting anti-smoking campaigns, stricter regulations on tobacco products, and rising consumer preference for healthier alternatives are further accelerating market expansion.

With a growing emphasis on smoking cessation programs, nicotine replacement therapies (NRT), and advanced drug formulations, the market is poised for substantial growth over the coming decade. Additionally, pharmaceutical advancements and the introduction of next-generation nicotine replacement solutions, such as prescription medications and behavioral support therapies, are making it easier for individuals to quit smoking successfully. The rising adoption of digital health platforms and mobile applications offering smoking cessation support is further contributing to the growing awareness and accessibility of these solutions.

The market is categorized by product type, including nicotine replacement therapy (NRT), drug therapy, and E-cigarettes and vapes. In 2024, the E-cigarettes and vapes segment dominated the market, accounting for 50% of the total share. The rising preference for these alternatives stems from their perceived reduced harm compared to conventional cigarettes. Young adults, particularly in North America and Europe, are leading the shift toward vaping devices, attracted by their convenience, variety of flavors, and technological advancements. Increasing regulatory approvals for controlled nicotine delivery through vaping products and growing investments by key players in innovative, harm-reduction technologies are further driving segment growth.

When examining the market by the route of administration, it is segmented into oral, transdermal, nasal, inhalation, and sublingual methods. In 2024, the inhalation segment led the market, holding a 50% share. The segment's dominance is largely attributed to the rising adoption of nicotine inhalers, vapes, and E-cigarettes. With continuous advancements in inhalation-based therapies, manufacturers are introducing novel nicotine inhalers designed to deliver controlled doses of nicotine, enhancing their effectiveness as a smoking cessation aid. Consumer preference for inhalation methods is driven by their ability to replicate the experience of traditional smoking while minimizing exposure to harmful chemicals.

The U.S. Smoking Cessation and Nicotine De-Addiction Market was valued at USD 8.9 billion in 2024 and is projected to reach USD 26.7 billion by 2034. The increasing prevalence of lung cancer and other smoking-related diseases in the U.S. is driving the demand for smoking cessation products. A growing number of smokers, particularly young adults, are actively seeking alternatives to traditional cigarettes, leading to a surge in demand for NRT, prescription medications, and behavioral therapies. The widespread adoption of E-cigarettes and vapes as a transitional aid for quitting smoking is further supporting market growth. Expanding research and development efforts, alongside government-backed anti-smoking initiatives, are expected to create significant opportunities for market players in the coming years.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing awareness of health risks associated with smoking
    • 3.2.1.2 Government regulations and anti-smoking campaigns
    • 3.2.1.3 Advancements in smoking cessation products
    • 3.2.1.4 Rise in smoking-related diseases and healthcare costs
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of smoking cessation products
    • 3.2.2.2 Psychological and physical addiction challenges
• 3.3 Growth potential analysis
• 3.4 Technology landscape
• 3.5 Regulatory landscape
• 3.6 Gap analysis
• 3.7 Patent analysis
• 3.8 Porter’s analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Nicotine replacement therapy
  • 5.2.1 Nicotine gum
  • 5.2.2 Nicotine patches
  • 5.2.3 Nicotine lozenges
  • 5.2.4 Nicotine nasal sprays
  • 5.2.5 Nicotine inhalers
• 5.3 Drug therapy
  • 5.3.1 Varenicline (Chantix)
  • 5.3.2 Bupropion (Zyban)
• 5.4 E-cigarettes and vapes

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Oral
• 6.3 Transdermal
• 6.4 Nasal
• 6.5 Inhalation
• 6.6 Sublingual

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 E-commerce

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alkalon
• 9.2 British American Tobacco
• 9.3 Cipla
• 9.4 Dr. Reddy’s Laboratories
• 9.5 GlaxoSmithKline
• 9.6 Imperial Brands
• 9.7 Johnson & Johnson
• 9.8 Lupin
• 9.9 NJOY
• 9.10 Novartis
• 9.11 Perrigo Company
• 9.12 Pfizer
• 9.13 Philip Morris International
• 9.14 Rusan Pharma
• 9.15 Zydus Group